Daihan Pharmaceutical Co.Ltd
Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions. Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.
Daihan Pharmaceutical Co.Ltd - Asset Resilience Ratio
Daihan Pharmaceutical Co.Ltd (023910) has an Asset Resilience Ratio of 11.95% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Daihan Pharmaceutical Co.Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Daihan Pharmaceutical Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩41.12 Billion | 11.95% |
| Total Liquid Assets | ₩41.12 Billion | 11.95% |
Asset Resilience Insights
- Moderate Liquidity: Daihan Pharmaceutical Co.Ltd has 11.95% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Daihan Pharmaceutical Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Daihan Pharmaceutical Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Daihan Pharmaceutical Co.Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Daihan Pharmaceutical Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 23.79% | ₩77.18 Billion | ₩324.41 Billion | -11.66pp |
| 2023-12-31 | 35.45% | ₩104.32 Billion | ₩294.25 Billion | +0.31pp |
| 2022-12-31 | 35.14% | ₩97.34 Billion | ₩276.98 Billion | -0.22pp |
| 2021-12-31 | 35.36% | ₩96.38 Billion | ₩272.54 Billion | +8.69pp |
| 2020-12-31 | 26.67% | ₩67.50 Billion | ₩253.09 Billion | +4.89pp |
| 2019-12-31 | 21.78% | ₩53.77 Billion | ₩246.85 Billion | +3.63pp |
| 2018-12-31 | 18.15% | ₩42.60 Billion | ₩234.75 Billion | +9.43pp |
| 2017-12-31 | 8.72% | ₩16.08 Billion | ₩184.40 Billion | +1.04pp |
| 2016-12-31 | 7.68% | ₩12.31 Billion | ₩160.31 Billion | +5.89pp |
| 2015-12-31 | 1.79% | ₩2.48 Billion | ₩138.83 Billion | -0.37pp |
| 2014-12-31 | 2.16% | ₩2.84 Billion | ₩131.61 Billion | -- |